Cardiology Department, Hospital General Universitario Gregorio Marañón, Doctor Esquerdo 46, 28007 Madrid, Spain.
Stem Cells Int. 2010 Nov 4;2010:579142. doi: 10.4061/2010/579142.
First randomized clinical trials have demonstrated that stem cell therapy can improve cardiac recovery after the acute phase of myocardial ischemia and in patients with chronic ischemic heart disease. Nevertheless, some trials have shown that conflicting results and uncertainties remain in the case of mechanisms of action and possible ways to improve clinical impact of stem cells in cardiac repair. In this paper we will examine the evidence available, analyze the main phase I and II randomized clinical trials and their limitations, discuss the key points in the design of future trials, and depict new directions of research in this fascinating field.
首次随机临床试验已经证明，干细胞疗法可以改善心肌缺血急性期和慢性缺血性心脏病患者的心脏恢复。然而，一些试验表明，在作用机制和可能提高干细胞在心脏修复中临床影响的方法方面，仍然存在相互矛盾的结果和不确定性。在本文中，我们将检查现有的证据，分析主要的 I 期和 II 期随机临床试验及其局限性，讨论未来试验设计的要点，并描绘这一迷人领域的新研究方向。
